You are here

FDA Approves IND Application for RP-A501 for Danon Disease

First Investigational Gene Therapy for Monogenic Heart Failure Syndrome

RP-A501 is Rocket Pharmaceuticals’ first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease.

Danon disease is a life-threatening heart-failure syndrome that develops during childhood and adolescence. The rare neuromuscular and cardiovascular disease is associated with severe cardiomyopathy, skeletal myopathies, and mild cognitive impairment.

Between 15,000 and 30,000 patients in the U.S. and Europe are estimated to have Danon disease. It is often fatal by the time patients reach their twenties or thirties as a result of progressive heart failure unless it is treated with a cardiac transplantation. However, this is not curative.

Rocket Pharmaceuticals plans to publish a comprehensive literature review of Danon cases and conduct a retrospective chart review in conjunction with the phase 1 clinical trial, which is expected to begin after June 2019.

Source: Rocket Pharmaceuticals, January 22, 2019

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Synergistic Effects Seen When Combined With Cisplatin in Mice